Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex

Abstract Background Older adults with type 2 diabetes (T2DM) are less likely to receive sodium–glucose cotransporter‐2 (SGLT2) inhibitors, despite their proven cardio‐renal benefits and safety. Whether this age‐related gap is driven by frailty, sex, or other factors remains unclear. Methods This observational study analysed data from adults registered in primary care during 2023, using the Groningen Initiative to Analyse Type 2 Diabetes Treatment (GIANTT) database. Eligibility for SGLT2 inhibitor treatment was determined based on the Dutch College of General Practitioners (NHG) guideline for T2DM. Prescription rates were assessed across demographics, comorbidities, and preceding medication use. Multivariable logistic regression models were used to assess the association of age and identify factors associated with SGLT2 inhibitor prescriptions. Results Among 10 241 adults with T2DM, 41% ( n = 4223) were eligible for SGLT2 inhibitor prescription. The prescription rate in the overall population was 15.2% and among eligible people was 25.5%. In people eligible for SGLT2 inhibitors, prescription rates were markedly lower with increasing age, with 37.6% in those aged